Flea, Tick Products Draw EPA ScrutinyJune 10, 2009 The U.S. Environmental Protection Agency is intensifying its evaluation of whether further restrictions on the use of spot-on pesticides for flea and tick control are necessary to better protect pets. The increased scrutiny applies to both over-the-counter and veterinary channel flea and tick products. An EPA spokesman said the move follows recent increases in reported incidents. More than 44,000 potential incidents associated with registered spot-on products were reported to the agency in 2008. Federal law requires EPA registrants to submit reports of possible adverse reactions that may be related to the use of their products whether or not the products were used properly and according to label instructions. A report does not indicate a cause-and-effect relationship between products and symptoms. EPA spokesman Dale Kemery said restrictions under consideration could include additional and more detailed label claims. “I just can’t say at this point,” Kemery said. “That’s what the evaluation will indicate.” Though flea and tick product incidents can involve spot-ons, sprays, collars and shampoos, most incidents reported to the EPA are related to EPA-registered spot-on products. Spot-ons are generally sold in tubes or vials and applied to one or more localized areas …
SPONSORED CONTENTThe clear reco for hidden stressOur therapeutic nutrition targets underlying stress in cats with GI or urinary issues — helping provide relief to pets and their humans. + Learn More
Economic Euthanasia On The RiseJune 10, 2009 Euthanasia can be the last act of love an owner shows her pet once disease or time has made death a greater comfort than life. This is the euthanasia veterinarians can accept and perform guilt-free. But now euthanasia has taken on a new and unsettling meaning for some veterinarians’ clients. Economic euthanasias are occurring at higher frequencies in practices where the community has been hit hard by the down economy. An increase in euthanasia performed when treatment is medically feasible leaves veterinarians to question how they can remain financially stable while helping clients and patients get what they need. The logic behind clients’ reasoning for pet euthanasia can be colorful, and veterinarians might question if they could have said something different to change the owner’s decision. But they are in a tough position when the treatment option is eliminated because of the cost. “We are seeing more euthanasias now than ever,” says Terry McInnis, office manager at After Hours Animal Emergency Clinic in Youngstown, Ohio. “The worst part is more clients are taking their pets home to die when they’re in need of treatment.” The After Hours clinic takes emergency visits for general practitioners …
Compounders In Spotlight After DeathsJune 10, 2009 Compounding pharmacies have come under increased scrutiny since the deaths of 21 polo horses shortly before the U.S. Open Polo Championship in Palm Beach County, Fla., in April. Franck’s Pharmacy of Ocala, Fla., admitted April 23, just days after the deaths, that it incorrectly prepared medication used to treat the horses. An internal investigation led by an outside lawyer “concluded that the strength of an ingredient in the medication was incorrect,” said Jennifer Beckett, Franck’s chief operations officer. The statement did not specify the ingredient, but Florida State Veterinarian Thomas Holt, DVM, said the deaths most likely were caused by a selenium overdose. At press time, it was unclear whether the team’s veterinarian specified an incorrect selenium dosage in the prescription or if the pharmacy caused the error. Beckett told Veterinary Practice News that she cannot comment because of the ongoing investigation. “We are waiting for the investigation to take its course,” she said. The larger question may not be who is at fault, but what effect this will have on the compounding industry. Will this tragedy lead to tighter regulations and increased scrutiny of compounding pharmacies? It may be too soon to …
Imulan Signs Vet Cancer Agreement With ImmunoPhotonicsJune 9, 2009 Imulan BioTherapeutics LLC of St. Joseph, Mo., recently signed an exclusive licensing agreement for ImmunoPhotonics Inc.’s apSTAR, a new laser device for cancer. apSTAR, named after Autologous Patient Specific Tumor Antigen Response, is a patented medical device technology that uses a specific laser wavelength to liberate tumor specific antigens and activate an immune response against the tumor cells. The companies indicate that studies have shown that the device improves the rate of primary and metastatic tumor regression and induce long term tumor immunity. Imulan’s new oncology division, Veterinary Cancer Therapeutics, has already started establishing cancer centers around the country using the apSTAR medical device technology. “We are very excited to be working with ImmunoPhotonics to advance this simple, yet comprehensive oncology breakthrough,” said Craig Woods, DVM, chief executive officer of Imulan and Veterinary Cancer Therapeutics. “The apSTAR laser will help shift the emphasis towards immune-based therapies and away from cytotoxic drug or radiation therapy for many types of cancer.” The device is currently available on a limited basis in the United States, with full scale production scheduled for later this year. ImmunoPhotonics is based in Roseland, Va. …
Animal Survivor Event Highlights Veterinary Medical AdvancesJune 8, 2009Four dogs and one cat were in the spotlight June 4 during the American College of Veterinary Internal Medicine’s Animal Survivor Media Event, which took place at the ACVIM Forum & Canadian Veterinary Medicine Association Convention in Montreal. The annual event gives insight into the medical advances that saves pets’ lives. “The ACVIM’s Animal Survivor is a wonderful opportunity to highlight animals that beat the odds,” said Jenn Armbruster, ACVIM communications and media relations manager. “With the help of their owners, general practitioners and ACVIM board-certified veterinary specialists, these animals overcame life-threatening illnesses to live life to the fullest once again.” One such example is Forrest Gumpy, a Jack Russell that was adopted by the McDougall family in 2007. Dixie Gumpy’s owners, specifically now 15-year-old Sarah-Simone McDougall, discovered his love for the water and decided to enter him into DockDogs diving events, leading him to compete with some of the top dogs in the world. However, Gumpy was struck with stage IV lymphoma shortly thereafter. Even though his fight with lymphoma had him going through many rounds of chemotherapy, and he relapsed three times, he remained happy and had a wonderful quality of life, according …
Southern Tier Veterinary Associates To Offer Wider Range Of Services With MergerJune 5, 2009 New York-based University Animal Hospital has merged with Southern Tier Veterinary Associates of Vestal, N.Y. The move was designed to better serve the area’s pets through a wider range of services, extensive diagnostic tools and advanced treatment technologies. The high cost of today’s technology can only be obtained through larger veterinary organizations, said John Crowell, DVM, of STVA. “The leaders of both practices are committed to providing the latest technology and the widest range of services for the area’s pets,” he said. “Combining our two practices is an effective way to do this.” As part of the merger agreement, University Animal Hospital will be consolidated at the STVA facility at 205 Front St. Medical records are being transferred and pet owners are being notified of the change. STVA said it is encouraging pet owners to learn more about the facility to help make the transition as smooth as possible. To help facilitate this, STVA will host an open house on June 11, from 10 a.m. – noon and from 5 p.m. – 7 p.m. A second open house will take place June 13, from 10 a.m. – noon. …
NRF Supports Bill Targeting Credit Card Processing FeesJune 5, 2009 The National Retail Federation (NRF), a retail trade association based in Washington, D.C., welcomed legislation introduced June 4 that would require Visa and MasterCard to negotiate credit card processing fees. According to NRF, such fees are “hidden” from consumers because they are not disclosed on receipts or credit card statements. The NRF said they cost the average household more than $400 a year. “Between the momentum built up since this bill passed the Judiciary Committee last year, the intense scrutiny of the financial services industry seen during the current economic crisis, and the credit card reform law signed last month, we think the perfect storm exists for Congress to do something about these unjustified hidden fees,” NRF Senior Vice President and General Counsel Mallory Duncan said in a statement. “In the middle of one of the worst recessions seen in decades, consumers can’t continue to pay artificially inflated prices just so the credit card industry can skim profits off the top. It’s time for these fees to be brought under control.” H.R. 2695, introduced by House Judiciary Committee Chairman John Conyers (D-Mich.), targets the so-called “interchange” fees merchants are charged by lending companies …
ChemNutra Inc. To Plead Guilty To Tainted Wheat GlutenJune 3, 2009 ChemNutra Inc., a Las Vegas-based ingredients broker that supplied tainted wheat gluten to pet-food manufacturers that led to the mass pet-food recalls of 2007, has agreed to plead guilty to 27 misdemeanor charges of distributing adulterated and/or misbranded food and one felony count of conspiracy to commit wire fraud. The company, and owners Stephen and Sally Miller, have signed a plea agreement and will formally change their pleas to guilty on June 16 at the U.S. District Court in Kansas City, Mo. Their trial had been scheduled to begin June 8, and the defense filed court documents confirming the plea change on May 27. Both Millers and the company were named in the indictment that was filed in February 2008. Terms of the plea agreement have not been disclosed. The penalty for each misdemeanor could be up to one year in prison and a $100,000 fine ($200,000 for the company); the penalty for the felony could be up to five years in prison and a $250,000 fine ($500,000 for the company). Restitution could also be ordered. The charges stemmed from ChemNutra receiving 13 shipments of wheat gluten between Nov. …
California Spay/Neuter Bill Heads To AssemblyJune 3, 2009 The California Senate on June 2 approved SB250, a measure that would require sterilization of most of the state’s cats and dogs. The 21-16 vote sent the bill to the Assembly for consideration. SB250, also known as the Pet Responsibility Act, failed in the Senate on June 1 by a vote of 16-15. It needed 21 votes to pass. A second vote led to the final approval June 2. The bill calls on owners to spay or neuter their cats at 6 months of age if the cats are allowed to roam at large. The bill also requires the sterilization of all dogs at 6 months old unless the owner gets an unaltered dog license. SB250 has been amended to authorize local governments to use existing procedures to issue intact dog licenses or to charge a fee for procedures related to the issuance, denial or revocation of unaltered dog licenses. Senate Majority Leader Dean Florez agreed June 2 to exempt hunting and working dogs from the measure and to ensure it will not apply to an animal escaping its yard for the first time. Click here to read the amended bill. …
FDA Approves Canine Cancer DrugJune 3, 2009 The U.S. Food and Drug Administration has approved Pfizer Animal Health’s Palladia (toceranib phosphate), the first drug developed specifically for the treatment of cancer in dogs. All cancer drugs now used in veterinary medicine originally were developed for use in humans and are not approved for animals. The prescription drug is approved to treat canine cutaneous mast cell tumors, a type of cancer responsible for about 20 percent of cases of canine skin tumors, according to the FDA. The New York company said it plans to introduce the product to boarded specialists within weeks to expand the body of clinical experience with the therapy. The drug will be available for purchase in early 2010. Palladia is an oral therapy indicated to treat Patnaik grade II or III recurrent cutaneous mast cell tumors with or without regional lymph node involvement. The drug belongs to the tyrosine kinase inhibitor class of compounds and works by blocking the activity of key receptors important for the development of blood vessels that supply tumors, as well as receptors critical for tumor survival, according to Pfizer Animal Health. The most common side effects associated with …
